Very excited about this collaboration with the PSPP! At Goldenrod Therapeutics, we are developing next-generation, small molecule, oral PDE4B inhibitors for the treatment of severely debilitating diseases that affect the central nervous system and for which current treatments are either inadequate or non-existent. Globally, about 1 in 5 people suffer from chronic pain, an extremely complex and debilitating condition which varies significantly between individuals. Unfortunately, highly addictive opioids are still the most commonly prescribed medications for chronic pain and, despite decades of effort, there are still no exceptional alternatives on the market. Goldenrod's non-opioid small molecule drugs have the potential to change this! Importantly, this partnership marks our second collaboration with an NIH Institutional Program - the first being our acceptance into NIDA's Addiction Treatment Discovery Program (ATDP) in 2022. We are thrilled to work with these key partners, among others, to advance Goldenrod's promising new treatments forward and to address the unmet needs of patients worldwide. #chronicpain #painresearch #paintherapeutics
We are excited to announce that one of our Fannin-founded companies, Goldenrod Therapeutics, has been accepted into the National Institute of Neurological Disorders and Stroke (NINDS) Preclinical Screening Platform for Pain (PSPP). In alignment with the NIH HEAL Initiative, the PSPP is an efficient, rigorous, one-stop screening resource to accelerate discovery of effective, non-addictive, non-opioid pain therapies. The program can assess in vitro and pharmacokinetic profiles, side effect profiles, abuse liability, and efficacy in models relevant to human pain conditions. Support from the PSPP Program will help accelerate the development of Goldenrod’s small molecule therapeutics towards treating chronic pain, which affects more than 51 million people in the United States alone. We look forward to this partnership and its potential for advancing these promising therapeutics towards the clinic. #Biotech #Neuroscience #Therapeutics #Innovation #Fannin
